For additional product information, please see
Press Release Details
Exagen Showcases Six Scientific Presentations at ACR’s First Virtual Annual Meeting in November 2020
Exagen Showcases Six Scientific Presentations at ACR’s First Virtual Annual Meeting in November 2020
October 21, 2020 at 4:05 PM EDT
Exagen’s Chief Scientific Officer,
Below is the list of accepted abstracts along with links to each:
Poster Presentation | Presented by
Title: Agreement of Hydroxychloroquine Blood Levels Between a University and
Session Title: SLE – Treatment Poster I
Session Time:
Oral Presentation | Presented by Yevgeniya Gartshteyn, MD | Abstract #1510
Title: Platelet-bound C4d is Associated with Platelet Activation and Arterial Thrombotic Events
Session Title: SLE – Diagnosis, Manifestations, & Outcomes II: Bench to Bedside (1507–1511)
Session Time:
Oral Presentation | Presented by
Title: Role of Platelet C4d in Thrombosis and Lupus Nephritis
Session Title: SLE – Diagnosis, Manifestations, & Outcomes III: Lupus Nephritis (1512–1516)
Session Time:
Poster Presentation | Presented by Yevgeniya Gartshteyn, MD | Abstract #1792
Title: Platelet-bound C4d is Associated with an Increased Risk of Arterial and Venous Thromboses in SLE
Session Title: SLE – Diagnosis, Manifestations, & Outcomes Poster III: Bench to Bedside
Session Time:
Poster Presentation | Presented by
Title: A
Session Title: SLE – Diagnosis, Manifestations, & Outcomes Poster III: Bench to Bedside
Session Time:
Poster Presentation | Presented by Jill Buyon, MD | Abstract #1808
Title: Erythrocyte Complement Receptor 1 (ECR1) and Erythrocyte Bound C4d (EC4d) Associate with Adverse Pregnancy Outcomes and Preeclampsia in Pregnant Women with Systemic Lupus Erythematosus (SLE)
Session Title: SLE – Diagnosis, Manifestations, & Outcomes Poster III: Bench to Bedside
Session Time:
* Abstracts will remain live until
About Exagen Inc.
Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. Exagen has developed and is commercializing a portfolio of innovative testing products under its AVISE® brand. Several of these products are based on our proprietary Cell-Bound Complement Activation Products, or CB-CAPs, technology. CB-CAPs assess the activation of the complement system, a biological pathway implicated in systemic lupus erythematosus, or SLE. Exagen’s goal is to enable rheumatologists to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including SLE and rheumatoid arthritis, or RA. Exagen’s model of integrating testing products and therapeutics positions Exagen to offer targeted solutions to rheumatologists and, ultimately, better serve patients. For more information, please visit www.Exagen.com
Forward Looking Statements
Exagen cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the company’s current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding the scientific abstracts for presentation at ACR Annual Conference and the potential to lead to increased adoption of any AVISE® test. The inclusion of forward-looking statements should not be regarded as a representation by Exagen that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Exagen’s business, including, without limitation: the COVID-19 pandemic may continue to adversely affect our business, financial condition and results of operations, Exagen’s commercial success depends upon attaining and maintaining significant market acceptance of its testing products and promoted therapeutics among rheumatologists, patients, third-party payers and others in the medical community; third party payers not providing coverage and adequate reimbursement for the company’s testing products or promoted therapeutics; the company’s ability to obtain and maintain intellectual property protection for its testing products; regulatory developments affecting the company’s business; risks associated with maintaining third-party partnerships and Exagen’s performance thereunder; and other risks described in the company’s prior press releases and the Company’s filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in the company’s Annual Report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Exagen undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Investors
Mike.Cavanaugh@westwicke.com
646.677.1838
Company
kadawi@exagen.com
760.477.5514
Source: Exagen Inc.